Agilius Biosciences LLC
Consultancy and advisory firm that partners with biopharmaceutical and medical device companies to advance medical countermeasures through government funding, commercialization support, and policy engagement. Services cover the full development lifecycle with emphasis on medical countermeasures, CBRN defense, combat casualty care, government contracting (including OTA), and deployment pathways such as strategic stockpiling and defense procurement.
Industries
Nr. of Employees
small (1-50)
Services
Advisory and execution support to secure government grants and contracts, including preparation for OTA and other government funding vehicles.
Program-level support through development, regulatory strategy, and commercialization to move countermeasures from discovery to deployment.
Strategic policy engagement and stakeholder management to position programs within defense and public-health procurement and policy frameworks.
Guidance on pathways for inclusion in government stockpiles and transition to acquisition and logistics agencies for operational deployment.
Embedded executive support to manage government relations, program execution, and commercialization while augmenting client leadership teams.
Advisory and execution support to secure government grants and contracts, including preparation for OTA and other government funding vehicles.
Program-level support through development, regulatory strategy, and commercialization to move countermeasures from discovery to deployment.
Strategic policy engagement and stakeholder management to position programs within defense and public-health procurement and policy frameworks.
Guidance on pathways for inclusion in government stockpiles and transition to acquisition and logistics agencies for operational deployment.
Embedded executive support to manage government relations, program execution, and commercialization while augmenting client leadership teams.
Expertise Areas
- Medical countermeasure development
- CBRN defense and preparedness
- Government funding and contracting (OTA, DoD, BARDA)
- Commercialization and market access for biodefense products
Key Technologies
- New approach methodologies (NAMs) / microphysiological systems (MPS)
- AI / machine learning for MCM development and biosurveillance
- High-performance computing for biosecurity
- On-demand / point-of-need manufacturing
News & Updates
Summary and takeaways from a BIO 2026 panel on accelerating medical countermeasure development, noting priorities such as NAMs, AI/ML, and potential government-private capital models.
Overview of a Medical Technology Enterprise Consortium (MTEC) pre-announcement soliciting medical prototype proposals with military relevance and a minimum TRL/KRL requirement.
Field report from BIO 2026 on how Canadian life-sciences companies are operationalizing dual-use strategies and the policy and funding landscape supporting defense-relevant applications.
Takeaways from the 2026 MTEC annual meeting highlighting government priorities such as chemical prophylaxis, host-directed therapeutics, on-demand manufacturing, and dual-use commercial utility.
Repost/summary describing the appointment of Mark Herzog to an advisory role at an external company and summarizing his biodefense engagement and government contracting experience.
Opinion/summary post reflecting on remarks from a defense official about evolving national security threats and implications for medical countermeasure preparedness and procurement.
Summary and takeaways from a BIO 2026 panel on accelerating medical countermeasure development, noting priorities such as NAMs, AI/ML, and potential government-private capital models.
Overview of a Medical Technology Enterprise Consortium (MTEC) pre-announcement soliciting medical prototype proposals with military relevance and a minimum TRL/KRL requirement.
Field report from BIO 2026 on how Canadian life-sciences companies are operationalizing dual-use strategies and the policy and funding landscape supporting defense-relevant applications.
Takeaways from the 2026 MTEC annual meeting highlighting government priorities such as chemical prophylaxis, host-directed therapeutics, on-demand manufacturing, and dual-use commercial utility.
Repost/summary describing the appointment of Mark Herzog to an advisory role at an external company and summarizing his biodefense engagement and government contracting experience.
Opinion/summary post reflecting on remarks from a defense official about evolving national security threats and implications for medical countermeasure preparedness and procurement.